Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 27 Mar 2017 |
| Orion Corporation: Decisions by the AGM on 22 March 2017 | 22 Mar 2017 |
| Orion Corporation: Organising meeting of the Board of Directors | 22 Mar 2017 |
| Orion Corporation: Managers' transactions - Turun mikrobiologien tiedesäätiö | 20 Mar 2017 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 2 Mar 2017 |